表紙
市場調查報告書

多發性囊胞腎(PKD)- 流行病學預測 2028年

Polycystic Kidney Disease (PKD) - Epidemiology Forecast to 2028

出版商 DelveInsight Business Research LLP 商品編碼 534949
出版日期 內容資訊 英文 70 Pages
商品交期: 最快1-2個工作天內
價格
多發性囊胞腎(PKD)- 流行病學預測 2028年 Polycystic Kidney Disease (PKD) - Epidemiology Forecast to 2028
出版日期: 2019年09月01日內容資訊: 英文 70 Pages
簡介

本報告提供主要新興國家(中國、台灣、沙烏地阿拉伯、阿拉伯聯合大公國、俄羅斯、土耳其、哥倫比亞、巴西、阿根廷、墨西哥)的多發性囊胞腎(PKD)的流行病學的相關調查,疾病概要,類型(多發性囊胞腎、平常染色體優性多發性囊胞腎)、各國罹患數的變化與預測詳細彙整。

目錄

第1章 重要洞察

第2章 多發性囊胞腎(PKD)市場概要

  • 分佈情形(成果值)
  • 分佈情形(預測值)

第3章 疾病的背景和概要

  • 簡介
  • 類型
  • 原因
  • 危險因素
  • 徵兆與症狀
  • 病理生理學
  • 診斷
  • 生物標記
  • 多發性囊胞腎(PKD)的併發症

第4章 流行病學及患者人口:各地區

  • 主要調查結果
  • 關鍵意見領袖的意見

第5章 新興國家(前十名國家)的多發性囊胞腎(PKD)的患病數

  • 主要新興國家的多發性囊胞腎(PKD)的總患病數
  • 平常染色體優性多發性囊胞腎(AD-PKD)的患病數

第6章 多發性囊胞腎(PKD)的流行病學:各地區

  • 亞洲、東歐
    • 中國
    • 台灣
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 俄羅斯
    • 土耳其
  • 南美
    • 哥倫比亞
    • 巴西
    • 阿根廷
    • 墨西哥

第7章 附錄

  • 調查手法

第8章 DelveInsight的服務內容

第9章 免責聲明

第10章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIEI0174

DelveInsight's 'Polycystic Kidney Disease (PKD)- Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Polycystic Kidney Disease in the 10 Emerging Markets (EM) ,i.e., Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan.

Geography Covered

  • Asia (China and Taiwan)
  • Middle East (Turkey, Saudi Arabia, UAE)
  • Eastern Europe (Russia)
  • LATAM (Brazil, Mexico, Colombia and Argentina)

Study Period: 2017-2028

Polycystic Kidney Disease Disease Understanding

Polycystic kidney disease (PKD) is part of a heterogeneous group of disorders characterized by renal cysts and numerous systemic and extrarenal manifestations. In patients with PKD, the kidneys contain multiple fluid-filled cysts. People with PKD can also have cysts in the liver (mainly) and problems in other organs, such as the heart and blood vessels in the brain. Although PKD is inherited monogenically, it is phenotypically, genetically, and allelically heterogeneous.

Polycystic Kidney Disease Epidemiology

The Polycystic Kidney Disease (PKD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 10 emerging countries. The epidemiology data for Polycystic Kidney Disease are studied through all possible division to give a better understanding about the Disease scenario in 10EM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Polycystic Kidney Disease Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population, total diagnosed cases of Polycystic Kidney Disease, gender-specific cases of PKD, clinical manifestations in Patients of ADPKD and transplant eligible PKD Patients) scenario of Polycystic Kidney Disease (PKD) in the 10EM covering Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan) from 2017-2028.

The DelveInsight report also provides the epidemiology trends observed in the 10EM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total number of prevalent cases of Polycystic Kidney Disease (PKD) in 10EM was found to be 1,912,820, in the year 2017.

Report Scope

  • The report covers detailed overview of Polycystic Kidney Disease explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Polycystic Kidney Disease in 10 emerging markets covering Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan. The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 10EM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by total prevalent population, total diagnosed cases of Polycystic Kidney Disease, gender-specific cases of PKD, clinical manifestations in Patients of ADPKD and transplant eligible PKD Patients in 10EM

Key strengths

  • 10 Year Forecast of Polycystic Kidney Disease epidemiology
  • 10EM Coverage
  • Total Prevalent Cases of PKDs
  • Prevalent Cases according to segmentation: total prevalent population, total diagnosed cases of Polycystic Kidney Disease, gender-specific cases of PKD, clinical manifestations in Patients of ADPKD and transplant eligible PKD Patients

Key assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. PKD Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of PKD in 2017
  • 2.2. Market Share (%) Distribution of PKD in 2028

3. Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Types
  • 3.3. Causes
  • 3.4. Risk Factors
  • 3.5. Signs and symptoms
  • 3.6. Pathophysiology
  • 3.7. Diagnosis
  • 3.8. Biomarkers
  • 3.9. Other Complications associated with PKD

4. Epidemiology and Patient Population - By Region

  • 4.1. Key Findings
  • 4.2. KOL views

5. Ten Emerging Markets (EM) Total Prevalent Population of Polycystic kidney disease (PKD)

  • 5.1. Total Prevalence of PKD in 10 Emerging Markets
  • 5.2. Prevalence of AD-PKD in 10 Emerging Markets

6. Region Wise-Epidemiology of Polycystic kidney disease (PKD)

  • 6.1. Asia and East Europe (China, Taiwan, Saudi Arabia, UAE, Russia, and Turkey)
    • 6.1.1. Assumptions and Rationale:
      • 6.1.1.1. China
      • 6.1.1.2. Total Prevalent Cases of PKD in China
      • 6.1.1.2.1. Prevalence of PKD by Types in China
      • 6.1.1.2.2. Prevalent Cases of PKD by Gender in China
      • 6.1.1.2.3. Diagnosed Prevalence of PKD in China
      • 6.1.1.2.4. Clinical Manifestations in Patients of ADPKD in China
      • 6.1.1.2.5. Transplant Eligible PKD Patients in China
      • 6.1.1.3. Taiwan
      • 6.1.1.3.1. Total Prevalent Cases of PKD in Taiwan
      • 6.1.1.3.2. Prevalence of PKD by Types in Taiwan
      • 6.1.1.3.3. Prevalent Cases of PKD by Gender in Taiwan
      • 6.1.1.3.4. Diagnosed Prevalence of PKD in Taiwan
      • 6.1.1.3.5. Clinical Manifestations in Patients of ADPKD in Taiwan
      • 6.1.1.3.6. Transplant Eligible PKD Patients in Taiwan
      • 6.1.1.4. Saudi Arabia
      • 6.1.1.4.1. Total Prevalent Cases of PKD in Saudi Arabia
      • 6.1.1.4.2. Prevalence of PKD by Types in Saudi Arabia
      • 6.1.1.4.3. Prevalent Cases of PKD by Gender in Saudi Arabia
      • 6.1.1.4.4. Diagnosed Prevalence of PKD in Saudi Arabia
      • 6.1.1.4.5. Clinical Manifestations in Patients of ADPKD in Saudi Arabia
      • 6.1.1.4.6. Transplant Eligible PKD Patients in Saudi Arabia
      • 6.1.1.5. UAE
      • 6.1.1.5.1. Total Prevalent Cases of PKD in UAE
      • 6.1.1.5.2. Prevalence of PKD by Types in UAE
      • 6.1.1.5.3. Prevalent Cases of PKD by Gender in UAE
      • 6.1.1.5.4. Diagnosed Prevalence of PKD in UAE
      • 6.1.1.5.5. Clinical Manifestations in Patients of ADPKD in UAE
      • 6.1.1.5.6. Transplant Eligible PKD Patients in UAE
      • 6.1.1.6. Turkey
      • 6.1.1.6.1. Total Prevalent Cases of PKD in Turkey
      • 6.1.1.6.2. Prevalence of PKD by Types in Turkey
      • 6.1.1.6.3. Prevalent Cases of PKD by Gender in Turkey
      • 6.1.1.6.4. Diagnosed Prevalence of PKD in Turkey
      • 6.1.1.6.5. Clinical Manifestations in Patients of ADPKD in Turkey
      • 6.1.1.6.6. Transplant Eligible PKD Patients in Turkey
      • 6.1.1.7. Russia
      • 6.1.1.7.1. Total Prevalent Cases of PKD in Russia
      • 6.1.1.7.2. Prevalence of PKD by Types in Russia
      • 6.1.1.7.3. Prevalent Cases of PKD by Gender in Russia
      • 6.1.1.7.4. Diagnosed Prevalence of PKD in Russia
      • 6.1.1.7.5. Clinical Manifestations in Patients of ADPKD in Russia
      • 6.1.1.7.6. Transplant Eligible PKD Patients in Russia
  • 6.2. LATAM (Colombia, Brazil, Argentina, and Mexico)
    • 6.2.1. Assumptions and Rationale:
      • 6.2.1.1. Colombia
      • 6.2.1.1.1. Total Prevalent Cases of PKD in Colombia
      • 6.2.1.1.2. Prevalence of PKD by Types in Colombia
      • 6.2.1.1.3. Prevalent Cases of PKD by Gender in Colombia
      • 6.2.1.1.4. Diagnosed Prevalence of PKD in Colombia
      • 6.2.1.1.5. Clinical Manifestations in Patients of ADPKD in Colombia
      • 6.2.1.1.6. Transplant Eligible PKD Patients in Colombia
      • 6.2.1.2. Brazil
      • 6.2.1.2.1. Total Prevalent Cases of PKD in Brazil
      • 6.2.1.2.2. Prevalence of PKD by Types in Brazil
      • 6.2.1.2.3. Prevalent Cases of PKD by Gender in Brazil
      • 6.2.1.2.4. Diagnosed Prevalence of PKD in Brazil
      • 6.2.1.2.5. Clinical Manifestations in Patients of ADPKD in Brazil
      • 6.2.1.2.6. Transplant Eligible PKD Patients in Brazil
      • 6.2.1.3. Argentina
      • 6.2.1.3.1. Total Prevalent Cases of PKD in Argentina
      • 6.2.1.3.2. Prevalence of PKD by Types in Argentina
      • 6.2.1.3.3. Prevalent Cases of PKD by Gender in Argentina
      • 6.2.1.3.4. Diagnosed Prevalence of PKD in Argentina
      • 6.2.1.3.5. Clinical Manifestations in Patients of ADPKD in Argentina
      • 6.2.1.3.6. Transplant Eligible PKD Patients in Argentina
      • 6.2.1.4. Mexico
      • 6.2.1.4.1. Total Prevalent Cases of PKD in Mexico
      • 6.2.1.4.2. Prevalence of PKD by Types in Mexico
      • 6.2.1.4.3. Prevalent Cases of PKD by Gender in Mexico
      • 6.2.1.4.4. Diagnosed Prevalence of PKD in Mexico
      • 6.2.1.4.5. Clinical Manifestations in Patients of ADPKD in Mexico
      • 6.2.1.4.6. Transplant Eligible PKD Patients in Mexico

7. Appendix

  • 7.1. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

List of Tables

  • Table 1: Total Prevalence of PKD in 10 Emerging Markets (2017-2028)
  • Table 2: Diagnosed Prevalence of ADPKD in 10 Emerging Markets (2017-2028)
  • Table 3: Total Prevalence Cases of PKD in China (2017-2028)
  • Table 4: Prevalence of PKD by Types in China (2017-2028)
  • Table 5: Prevalence of PKD by Gender in China (2017-2028)
  • Table 6: Diagnosed Prevalence of PKD in China (2017-2028)
  • Table 7: Clinical Manifestations in Patients of ADPKD in China (2017-2028)
  • Table 8: Transplant Eligible PKD Patients in China (2017-2028)
  • Table 9: Total Prevalence Cases of PKD in Taiwan (2017-2028)
  • Table 10: Prevalence of PKD by Types in Taiwan (2017-2028)
  • Table 11: Prevalence of PKD by Gender in Taiwan (2017-2028)
  • Table 12: Diagnosed Prevalence of PKD in Taiwan (2017-2028)
  • Table 13: Clinical Manifestations in Patients of ADPKD in Taiwan (2017-2028)
  • Table 14: Transplant Eligible PKD Patients in Taiwan (2017-2028)
  • Table 15: Total Prevalence Cases of PKD in Saudi Arabia (2017-2028)
  • Table 16: Prevalence of PKD by Types in Saudi Arabia (2017-2028)
  • Table 17: Prevalence of PKD by Gender in Saudi Arabia (2017-2028)
  • Table 18: Diagnosed Prevalence of PKD in Saudi Arabia (2017-2028)
  • Table 19: Clinical Manifestations in Patients of ADPKD in Saudi Arabia (2017-2028)
  • Table 20: Transplant Eligible PKD Patients in Saudi Arabia (2017-2028)
  • Table 21: Total Prevalence Cases of PKD in UAE (2017-2028)
  • Table 22: Prevalence of PKD by Types in UAE (2017-2028)
  • Table 23: Prevalence of PKD by Gender in UAE (2017-2028)
  • Table 24: Diagnosed Prevalence of PKD in UAE (2017-2028)
  • Table 25: Clinical Manifestations in Patients of ADPKD in UAE (2017-2028)
  • Table 26: Transplant Eligible PKD Patients in UAE ( (2017-2028)
  • Table 27: Total Prevalence Cases of PKD in Turkey (2017-2028)
  • Table 28: Prevalence of PKD by Types in Turkey (2017-2028)
  • Table 29: Prevalence of PKD by Gender in Turkey (2017-2028)
  • Table 30: Diagnosed Prevalence of PKD in Turkey (2017-2028)
  • Table 31: Clinical Manifestations in Patients of ADPKD in Turkey (2017-2028)
  • Table 32: Transplant Eligible PKD Patients in Turkey (2017-2028)
  • Table 33: Total Prevalence Cases of PKD in Russia (2017-2028)
  • Table 34: Prevalence of PKD by Types in Russia (2017-2028)
  • Table 35: Prevalence of PKD by Gender in Russia (2017-2028)
  • Table 36: Diagnosed Prevalence of PKD in Russia (2017-2028)
  • Table 37: Clinical Manifestations in Patients of ADPKD in Russia (2017-2028)
  • Table 38: Transplant Eligible PKD Patients in Russia (2017-2028)
  • Table 39: Total Prevalence Cases of PKD in Colombia (2017-2028)
  • Table 40: Prevalence of PKD by Types in Colombia (2017-2028)
  • Table 41: Prevalence of PKD by Gender in Colombia (2017-2028)
  • Table 42: Diagnosed Prevalence of PKD in Colombia (2017-2028)
  • Table 43: Clinical Manifestations in Patients of ADPKD in Colombia (2017-2028)
  • Table 44: Transplant Eligible PKD Patients in Colombia (2017-2028)
  • Table 45: Total Prevalence Cases of PKD in Brazil (2017-2028)
  • Table 46: Prevalence of PKD by Types in Brazil (2017-2028)
  • Table 47: Prevalence of PKD by Gender in Brazil (2017-2028)
  • Table 48: Diagnosed Prevalence of PKD in Brazil (2017-2028)
  • Table 49: Clinical Manifestations in Patients of ADPKD in Brazil (2017-2028)
  • Table 50: Transplant Eligible PKD Patients in Brazil (2017-2028)
  • Table 51: Total Prevalence Cases of PKD in Argentina (2017-2028)
  • Table 52: Prevalence of PKD by Types in Argentina (2017-2028)
  • Table 53: Prevalence of PKD by Gender in Argentina (2017-2028)
  • Table 54: Diagnosed Prevalence of PKD in Argentina (2017-2028)
  • Table 55: Clinical Manifestations in Patients of ADPKD in Argentina (2017-2028)
  • Table 56: Transplant Eligible PKD Patients in Argentina (2017-2028)
  • Table 57: Total Prevalence Cases of PKD in Mexico (2017-2028)
  • Table 58: Prevalence of PKD by Types in Mexico (2017-2028)
  • Table 59: Prevalence of PKD by Gender in Mexico (2017-2028)
  • Table 60: Diagnosed Prevalence of PKD in Mexico (2017-2028)
  • Table 61: Clinical Manifestations in Patients of ADPKD in Mexico (2017-2028)
  • Table 62: Transplant Eligible PKD Patients in Mexico (2017-2028)

List of Figures

  • Figure 1: Polycystic kidney disease Signs and symptoms
  • Figure 2: Domain organization of proteins implicated in polycystic kidney disease
  • Figure 3: Mechanisms of cyst formation and expansion: a) PCI-PC2 localization b) ciliary localization of the polycystins
  • Figure 4: Renal fibrosis in autosomal dominant polycystic kidney disease
  • Figure 5: Renal fibrosis in autosomal dominant polycystic kidney disease
  • Figure 6: Ultrasonography criteria for an ADPKD diagnosis in at-risk individual
  • Figure 7: Potential Biomarkers in polycystic kidney disease
  • Figure 9: Total Prevalence of PKD in 10 Emerging Markets (2017-2028)
  • Figure 10: Diagnosed Prevalence of ADPKD in 10 Emerging Markets (2017-2028)
  • Figure 11: Total Prevalence Cases of PKD in China (2017-2028)
  • Figure 12: Prevalence of PKD by Types in China (2017-2028)
  • Figure 13: Prevalent Cases by gender of PKD in China (2017-2028)
  • Figure 14: Diagnosed Prevalence of PKD in China (2017-2028)
  • Figure 15: Clinical Manifestations in Patients of ADPKD in China (2017-2028)
  • Figure 16: Transplant Eligible PKD Patients in China (2017-2028)
  • Figure 17: Total Prevalence Cases of PKD in Taiwan (2017-2028)
  • Figure 18: Prevalence of PKD by Types in Taiwan (2017-2028)
  • Figure 19: Prevalent Cases by gender of PKD in Taiwan (2017-2028)
  • Figure 20: Diagnosed Prevalence of PKD in Taiwan (2017-2028)
  • Figure 21: Clinical Manifestations in Patients of ADPKD in Taiwan (2017-2028)
  • Figure 22: Transplant Eligible PKD Patients in Taiwan (2017-2028)
  • Figure 23: Total Prevalence Cases of PKD in Saudi Arabia (2017-2028)
  • Figure 24: Prevalence of PKD by Types in Saudi Arabia (2017-2028)
  • Figure 25: Prevalent Cases by gender of PKD in Saudi Arabia (2017-2028)
  • Figure 26: Diagnosed Prevalence of PKD in Saudi Arabia (2017-2028)
  • Figure 27: Clinical Manifestations in Patients of ADPKD in Saudi Arabia (2017-2028)
  • Figure 28: Transplant Eligible PKD Patients in Saudi Arabia (2017-2028)
  • Figure 29: Total Prevalence Cases of PKD in UAE (2017-2028)
  • Figure 30: Prevalence of PKD by Types in UAE (2017-2028)
  • Figure 31: Prevalent Cases by gender of PKD in UAE (2017-2028)
  • Figure 32: Diagnosed Prevalence of PKD in UAE (2017-2028)
  • Figure 33: Clinical Manifestations in Patients of ADPKD in UAE (2017-2028)
  • Figure 34: Transplant Eligible PKD Patients in UAE (2017-2028)
  • Figure 35: Total Prevalence Cases of PKD in Turkey (2017-2028)
  • Figure 36: Prevalence of PKD by Types in Turkey (2017-2028)
  • Figure 37: Prevalent Cases by gender of PKD in Turkey (2017-2028)
  • Figure 38: Diagnosed Prevalence of PKD in Turkey (2017-2028)
  • Figure 39: Clinical Manifestations in Patients of ADPKD in Turkey (2017-2028)
  • Figure 40: Transplant Eligible PKD Patients in Turkey (2017-2028)
  • Figure 41: Total Prevalence Cases of PKD in Russia (2017-2028)
  • Figure 42: Prevalence of PKD by Types in Russia (2017-2028)
  • Figure 43: Prevalent Cases by gender of PKD in Russia (2017-2028)
  • Figure 44: Diagnosed Prevalence of PKD in Russia (2017-2028)
  • Figure 45: Clinical Manifestations in Patients of ADPKD in Russia (2017-2028)
  • Figure 46: Transplant Eligible PKD Patients in Russia (2017-2028)
  • Figure 47: Total Prevalence Cases of PKD in Colombia (2017-2028)
  • Figure 48: Prevalence of PKD by Types in Colombia (2017-2028)
  • Figure 49: Prevalent Cases by gender of PKD in Colombia (2017-2028)
  • Figure 50: Diagnosed Prevalence of PKD in Colombia (2017-2028)
  • Figure 51: Clinical Manifestations in Patients of ADPKD in Colombia (2017-2028)
  • Figure 52: Transplant Eligible PKD Patients in Colombia (2017-2028)
  • Figure 53: Total Prevalence Cases of PKD in Brazil (2017-2028)
  • Figure 54: Prevalence of PKD by Types in Brazil (2017-2028)
  • Figure 55: Prevalent Cases by Gender of PKD in Brazil (2017-2028)
  • Figure 56: Diagnosed Prevalence of PKD in Brazil (2017-2028)
  • Figure 57: Clinical Manifestations in Patients of ADPKD in Brazil (2017-2028)
  • Figure 58: Transplant Eligible PKD Patients in Brazil (2017-2028)
  • Figure 59: Total Prevalence Cases of PKD in Argentina (2017-2028)
  • Figure 60: Prevalence of PKD by Types in Argentina (2017-2028)
  • Figure 61: Prevalent Cases by Gender of PKD in Argentina (2017-2028)
  • Figure 62: Diagnosed Prevalence of PKD in Argentina (2017-2028)
  • Figure 63: Clinical Manifestations in Patients of ADPKD in Argentina (2017-2028)
  • Figure 64: Transplant Eligible PKD Patients in Argentina (2017-2028)
  • Figure 65: Total Prevalence Cases of PKD in Mexico (2017-2028)
  • Figure 66: Prevalence of PKD by Types in Mexico (2017-2028)
  • Figure 67: Prevalent Cases by Gender of PKD in Mexico (2017-2028)
  • Figure 68: Diagnosed Prevalence of PKD in Mexico (2017-2028)
  • Figure 69: Clinical Manifestations in Patients of ADPKD in Mexico (2017-2028)
  • Figure 70: Transplant Eligible PKD Patients in Mexico (2017-2028)